LANGHORNE, PA — NEXGEL, Inc. (NASDAQ: NXGL) announced an expanded collaboration with European pharmaceutical and consumer health leader STADA Arzneimittel AG, aiming to bring a new suite of health products to North American consumers.
The broadened partnership will focus on the development and launch of innovative digestive enzyme formulas as well as advanced solutions for scar and stretch mark care. These product lines mark NEXGEL’s continued push into high-demand wellness categories, leveraging its expertise in advanced hydrogel technologies.
As part of the expansion, STADA will provide $1 million in non-dilutive capital to NEXGEL, supporting product development, launch activities, and marketing initiatives.
“This next phase of our partnership reflects a shared outlook that there is an opportunity in bringing these health solutions to consumers across North America,” said Adam Levy, Chief Executive Officer of NEXGEL. “We are grateful for STADA’s financial support, which will accelerate our joint go-to-market strategy.”
The agreement underscores NEXGEL’s strategy of aligning with established global partners to scale its innovative offerings, while STADA strengthens its foothold in the growing North American consumer health market.
With this financial boost and expanded collaboration, NEXGEL is positioning itself to capture new market segments and further its reputation for delivering specialized health and wellness solutions backed by advanced material science.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.